Schering-Plough obtained exclusive worldwide rights outside the U.S., Japan and certain small markets to distribute, market and sell CAELYX, a liposomal formulation of the cancer drug doxorubicin. SEQU sells the product in the U.S. under the trade name DOXIL to treat Kaposi's sarcoma. ...
